- Home
- BDRX vs LGVN Comparison
BDRX vs LGVN Comparison
Compare BDRX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | LGVN |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 17.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BDRX | LGVN |
|---|---|---|
| Price | $5.02 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 1.7M | 408.1K |
| Earning Date | 09-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.58 | $0.58 |
| 52 Week High | $92.00 | $2.24 |
Technical Indicators
Market Signals| Indicator | BDRX | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 39.34 |
| Support Level | $4.00 | $0.58 |
| Resistance Level | $8.94 | $0.65 |
| Average True Range (ATR) | 1.25 | 0.04 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 21.54 | 26.77 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.